fda warning compounding semaglutide october 2025 Warns on Certain Forms of Compounded Diabetes advocacy group discourages use

Fatty Acid Modification# A defining structural feature of retatrutide is the C18 (octadecanedioic acid) fatty diacid moiety conjugated at Lys30 via a chemical linker

this warrants ongoing monitoring No unexpected serious cardiovascular signals were identified during the limited Phase 2 follow-up period, though the trials were neither designed nor powered to assess cardiovascular outcomes, and longer-term data are not yet available At present, the overall safety profile appears broadly consistent with other GLP-1-based therapies, but definitive conclusions cannot be drawn until Phase 3 data and post-marketing surveillance are available

TRIUMPH-1 is the trial that will determine whether that vision becomes reality for retatrutide

Before determining that a shortage is resolved, FDA considers a variety of factors, including the company's ability to meet current and historical demand, the amount in a manufacturers stock, affected market share, ability of alternate manufacturers to cover the demand, and confirmed market stabilization